SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

Antonio C. Fuentes-Fayos(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raúl M. Luque(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition)
Journal of Experimental & Clinical Cancer Research
January 27, 2022
10.1186/s13046-022-02241-4
Cited by 40

Related Papers

Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3
|Brain|2020|103
Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence
|EBioMedicine|2023|45
Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and <scp>IGF</scp>1
|Journal of Cellular and Molecular Medicine|2017|23
Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells
|Antioxidants|2021|20
Adipokines and Their Receptors Are Widely Expressed and Distinctly Regulated by the Metabolic Environment in the Prostate of Male Mice: Direct Role Under Normal and Tumoral Conditions
|Endocrinology|2017|13